Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed +170.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Shares outstanding changed +63.4% from the comparable as-filed period. The change ranks at the 75th percentile of 8 prior comparable changes.
Revenue changed -100.0% from the comparable as-filed period.
Stock-based compensation changed -27.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current assets changed -31.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Total assets changed -31.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Research & development changed -15.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash flow changed -6.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating income changed -0.9% from the comparable as-filed period.
Net income changed -5.0% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.